Clinical and pathologic characteristics of 29 patients with CHL studied by GEP of microdissected HRS cells
| . | Treatment success (no progression or relapse) . | Treatment failure (progression or relapse) . | P . |
|---|---|---|---|
| N | 15 | 14 | |
| Median age, y | 41 | 35 | NS |
| Sex, male, % | 60 | 72 | NS |
| Histology | NS | ||
| Nodular sclerosis | 14 | 12 | |
| Mixed cellularity | 1 | 2 | |
| Lymphocyte-rich | 0 | 0 | |
| Lymphocyte-depleted | 0 | 0 | |
| NOS (not classifiable) | 0 | 0 | |
| Stage, % | .082 | ||
| I | 13 | 0 | |
| II | 60 | 29 | |
| III | 20 | 43 | |
| IV | 7 | 29 | |
| B-symptoms, % | 13 | 43 | .075 |
| Median mass size, cm | 6.6 | 6.6 | NS |
| ≥ 10 cm, % | 27 | 29 | NS |
| High risk, IPS ≥ 4, % | 20 | 14 | NS |
| Primary treatment | NS | ||
| ABVD type ± radiation, % | 93 | 93 | |
| Extended field radiation alone, % | 7 | 7 |
| . | Treatment success (no progression or relapse) . | Treatment failure (progression or relapse) . | P . |
|---|---|---|---|
| N | 15 | 14 | |
| Median age, y | 41 | 35 | NS |
| Sex, male, % | 60 | 72 | NS |
| Histology | NS | ||
| Nodular sclerosis | 14 | 12 | |
| Mixed cellularity | 1 | 2 | |
| Lymphocyte-rich | 0 | 0 | |
| Lymphocyte-depleted | 0 | 0 | |
| NOS (not classifiable) | 0 | 0 | |
| Stage, % | .082 | ||
| I | 13 | 0 | |
| II | 60 | 29 | |
| III | 20 | 43 | |
| IV | 7 | 29 | |
| B-symptoms, % | 13 | 43 | .075 |
| Median mass size, cm | 6.6 | 6.6 | NS |
| ≥ 10 cm, % | 27 | 29 | NS |
| High risk, IPS ≥ 4, % | 20 | 14 | NS |
| Primary treatment | NS | ||
| ABVD type ± radiation, % | 93 | 93 | |
| Extended field radiation alone, % | 7 | 7 |
NS indicates not significant.